In this article, we will discuss Durvalumab (Dosage Overview). So, let’s get started.
Durvalumab is indicated for the treatment of patients with locally advanced or metastatic urothelial
• have disease progression during or following platinum-containing chemotherapy.
• have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Non-Small Cell Lung Cancer
Durvalumab is indicated for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Recommended Dosage for Urothelial Carcinoma
The recommended dose of Durvalumab is 10 mg/kg administered as an intravenous infusion over 60 minutes every 2 weeks, until disease progression or unacceptable toxicity.
Recommended Dosage for NSCLC
The recommended dose of Durvalumab is 10 mg/kg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression, unacceptable toxicity, or a maximum of 12 months.